pharmacie et médicaments – Fin du plafond des remises génériques à hauteur de 40 %

This written question concerns the potential end of a 40% cap on discounts for generic medicines in France. It seeks clarification on the implications for the pharmaceutical market and public health spending. The question addresses the impact on pharmaceutical companies, pharmacies, and ultimately, patients. It explores how changes to discount caps could affect the availability and affordability of medicines.